Marketing Orthopedic Devices to Surgeons and the Committees Behind Them

Bottom line: Marketing an orthopedic implant means selling to two audiences with one message. The surgeon decides clinically and cares about technique, outcomes, instrumentation, and how much the operating room routine has to change. The hospital's value analysis committee decides commercially and cares about total cost per case, training and inventory burden, and what happens to the implants already on the shelf. A surgeon who wants the implant cannot buy it, and a committee that approves it cannot make anyone use it. Plan for both approvals, and give the surgeon the material they need to make the case inside their own institution.

This is a primer, not legal, regulatory, or clinical advice. Run every claim through your own regulatory affairs and legal teams, and every clinical characterization through your medical or clinical affairs team.

Who this guide is for. This is written for the marketing or commercial team at a medical device company that sells orthopedic implants, instruments, or the technology around them, and needs an adoption plan. It is about reaching surgeons and the hospital committees that authorize the purchase. It is not about marketing a surgical practice to patients. If you are a surgeon or a practice administrator looking to attract patients, this is the wrong page, and nothing below will help you.

Most orthopedic go-to-market plans are built as if the surgeon were the customer. The surgeon is the user, the advocate, and frequently the person who kills the deal, but in a hospital setting the surgeon is rarely the purchaser. The plan that works maps every person who can say no, and gives each of them the one thing they need.

The Buyer Chain: Who Has to Say Yes

An orthopedic implant purchase passes through a chain of approvals. The names differ by institution, and a small community hospital may collapse four of these roles into one person while a large integrated delivery network may add two more, but the functions are consistent. One row is different in kind and it is worth being precise about it: the value analysis committee is a body, not a person, and its members are drawn from the same functions listed above and below it in the table. It appears as its own row because it is a distinct gate with its own calendar and its own paperwork, not because it is another individual to go find.

Two things follow from that table, and they are the whole guide in miniature.

First, there are two separate approvals, clinical and commercial, and they are not substitutes. A device that clears the committee but that no surgeon wants sits on a shelf. A device that every surgeon wants but that never clears the committee never arrives. Companies tend to be strong on one side and blind on the other, usually because the commercial team is built from clinically-minded reps or from purely commercial ones, rarely both.

Second, the person who carries your case into the room is not you. Most institutions exclude vendors from the meeting outright. Some will bring a vendor in to answer one narrow technical question. What does not vary is the deliberation and the vote: those are closed, and requesters and any invited guest are asked to leave before them. Assume as your planning case that nobody speaks for the product at all and the committee works from the submitted form, because at a great many institutions that is exactly what happens. The form is what the committee sees, and what the surgeon can carry in is the ceiling on how well the case gets made. That single fact should reorganize a marketing plan, because it means a large share of your output exists to be transmitted by somebody else, compressed, in a room you are not in. Material designed for that job looks different from material designed to impress.

For the persona-level detail behind each of these roles, the module has dedicated pieces: how orthopedic surgeons evaluate a device, marketing to hospital procurement, and reaching the hospital C-suite. This guide is the connective tissue between them.

What the Surgeon Decides, and What They Cannot

The most expensive misunderstanding in orthopedic marketing is treating surgeon enthusiasm as a closed sale.

What the surgeon genuinely owns

• Whether the device is clinically appropriate for the cases they do
• Whether the surgical technique fits how they already operate, and how much retraining the change requires
• Whether the instrumentation is usable, which is a hands-on judgment no brochure resolves
• What happens in the revision or failure case, which experienced surgeons ask about early and new companies answer late
• Whether they will use it, which is an absolute veto that no committee approval overrides

What the surgeon does not own

• Whether the institution can purchase the product at all
• The price, the terms, or the contract vehicle
• Whether the item can be added to the catalog and the item master
• Whether the sterile processing department can support another instrument set
• Whether the health system's standardization initiative permits a new supplier in that category

The gap between those two lists is the reason a surgeon relationship converts at a rate that surprises people who came from other industries. The surgeon can want your implant sincerely and still be unable to obtain it, and if the internal process defeats them once, they usually do not try twice.

The implication: your real deliverable is an advocacy packet

If the surgeon is the person who carries the case, then the most valuable thing marketing produces is not the brochure. It is the material that survives being handed to a committee by a busy clinician who is preparing it between cases.

That material has a specific shape. It is short. It leads with what the device is authorized to do rather than with the value proposition. It states cost in terms of a case rather than a unit. It answers the conversion question before it is asked. It cites evidence that a non-clinician can locate and verify. And it is formatted to be attached to a form rather than admired.

Every claim in that packet is a promotional claim, and it carries the same obligations as anything else the company publishes. The review workflow is covered in medical device promotional review, and it is worth reading before the packet is written rather than after regulatory rejects it.

How a New Implant Displaces an Incumbent

Orthopedics has real, durable brand preference, and outsiders consistently underestimate how sticky it is. The drivers are specific, and naming them correctly is the difference between a displacement plan and a wish.

Training lineage comes first. Surgeons tend to keep using the system they learned on in residency and fellowship, and that imprint lasts years into independent practice. Accumulated hands-on familiarity comes second, and it is larger than it sounds, because an implant system is a workflow rather than an object: a surgeon who knows a system knows the sequence of the steps, the feel of the instruments, and what the recovery move is when the case does not go the way the technique guide describes. Confidence in the failure pathway comes third, meaning the sizes, augments, and revision options that exist when the straightforward case is not the case in front of them.

Two more drivers matter as much and get left out of most plans. Field support is one: in orthopedics the rep is in the room, manages the tray, and knows the system, and a surgeon's loyalty frequently attaches to that support at least as much as to the manufacturer. Installed enabling technology is the other: once a surgeon is working on a robotic or navigation platform, the implants that platform supports are the implants that are practical to use, and the platform decision has quietly made the implant decision.

The switching cost is procedural and reputational for the surgeon, whose name is on the operative note and who carries the outcome personally, and economic and operational for the institution, which is absorbing new trays, new inventory, and a slower list. Those are two different costs, felt by two different people, and a plan that answers only one of them stalls at the other.

That means most orthopedic marketing is not a greenfield sale. It is a displacement, and displacements do not happen because a competitor's message was better. They happen when a window opens.

The windows that actually open

• A surgeon joins or leaves. New surgeons arrive with the preferences their training gave them, which is the single most reliable displacement event in the category.
• The incumbent has a quality, supply, or recall event. Uncomfortable to plan around, but institutions do reopen categories after one.
• A contract or agreement reaches renewal. The commercial window and the clinical window rarely align on their own, and aligning them is a marketing job.
• A technique or indication shifts. A change in how the procedure is done reopens the question of what it is done with.
• An enabling technology platform arrives or gets replaced. A robot or navigation system entering the room reopens the implant question for every case that runs on it, and closes it for everything the platform does not support.
• Cost pressure forces standardization. This one cuts both ways: standardization can lock you out of a category permanently, or it can be the reason an institution consolidates onto you.
• A service line consolidates or a system acquires the hospital. Purchasing authority moves, and everything previously settled is briefly unsettled.

A pipeline built without reference to these windows is a pipeline built on hope. A named-account program that knows which window is open at which institution is a fundamentally different exercise, and it is the point where account-based work stops being a buzzword in medtech.

Make the switching cost small and visible

The incumbent's advantage is not its product. It is that switching has a cost the surgeon and the institution both feel: retraining, new trays, a period of slower cases, unfamiliar instruments, and a stock of product already purchased.

Marketing's job in a displacement is to make that cost explicit and then to shrink it, in that order. Explicit, because an unnamed cost is assumed to be larger than it is. Shrunk, because every element of it has a countermeasure that belongs in the plan: a training and proctoring path, an instrument set that respects processing capacity, a defined conversion sequence for existing inventory, and a first-case support commitment.

One caution before you build a comparison, because a displacement section that ignores comparative claims is not a neutral omission. A claim that your device is better than a named competitor, or better on a specific endpoint, is a comparative claim, and a comparative claim needs head-to-head evidence on that comparison and that endpoint. Two single-arm studies read side by side are not head-to-head evidence, and this is the most common way a displacement deck becomes a regulatory problem. There is a second exposure that surprises marketers. A comparative claim can also describe an intended use, and for a device cleared through a 510(k) the operative question is whether the communication would require a new 510(k), which is a different test from the consistency factors most published content quotes. Both questions belong to regulatory before the deck exists, not after. The safer and frequently more persuasive move is an attribute claim that stands on its own evidence: describe what your device does and what was measured, without ranking it. The workflow behind both is in medical device promotional review.

Building the Value Analysis Dossier

This is where most orthopedic go-to-market plans have nothing at all, and it is the section worth stealing.

A value analysis committee exists to decide whether a product enters the catalog. Value analysis is still the dominant name in US hospitals, and value analysis team, new product committee, technology assessment committee, product standardization committee, and clinical product council all describe the same function. Learn the institution's own term and use it. Large systems commonly run a facility-level body underneath a system-level one, and the system level is usually where standardization is actually decided, which is a distinction worth establishing before you invest a year in one hospital.

The membership is cross-functional and it is the same set of functions from section 1: a physician or service line clinical lead, perioperative nursing, supply chain, and finance, generally with quality represented. For an orthopedic implant specifically, the reviews that decide the outcome often come from people who are not standing members at all. Sterile processing and infection prevention get pulled in because of the trays and the reprocessing, and clinical or biomedical engineering and IT get pulled in the moment the product connects to anything. Plan for those consults rather than being surprised by them. One more structural fact: if there is a capital component, capital almost always runs a second track on the annual budget calendar, so clearing value analysis is not the same thing as being purchasable.

The committee is not evaluating your marketing. It is evaluating a request, submitted by someone inside the institution, against a standard set of questions. Your job is to make sure every one of those questions has an answer attached before the request is filed.

What goes in the dossier

The instrument row is the one device marketers underweight and sterile processing never does. Anything arriving from outside the hospital is treated as contaminated on arrival and gets a full decontamination, inspection, assembly, and sterilization cycle at the receiving facility regardless of what happened to it at the last one, and a single orthopedic set can carry hundreds of implants and instruments that all have to be inspected and accounted for. That is why loaner sets have to arrive far enough ahead of the case to complete that cycle, why there are recommended ceilings on set weight, and why a tray that is heavier or more complicated than the incumbent's is a substantive objection rather than a detail to be smoothed over. A conversion plan that ignores it produces approved products that never get scheduled, which is a worse outcome than a rejection because it looks like a win for a quarter.

Two other rows in that table carry regulatory weight and should not be drafted from general marketing knowledge.

The coding and payment row is the sharper one, and the reason is that a provider may bill in reliance on what a device company tells them. That puts these statements in a different category from product claims, and two bodies of law meet on this single row.

On the FDA side, health care economic information provided to a payor, a formulary committee, or another similar entity with knowledge and expertise in health care economic analysis is treated as its own category under section 502(a) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 352(a). That provision, which Congress extended to devices in 2023, conditions such information on relating to an indication authorized under the device's clearance, granting, or approval, on being based on competent and reliable scientific evidence, and on carrying a conspicuous and prominent statement of any material differences between the information and the authorized labeling. Whether a particular hospital committee is one of those entities is a determination for regulatory and legal, not a question a marketing team settles on its own, and the answer shapes what the dossier's economic material is allowed to look like.

On the fraud and abuse side, a company whose coding or billing direction a provider relies on can face exposure under the False Claims Act at 31 U.S.C. 3729(a)(1) for causing the submission of a false claim. That exposure does not require anyone to have intended it.

The workable rule for a marketing team is short. This row is produced by reimbursement or market access, is reviewed the way a regulatory document is reviewed, and describes how coding and coverage work rather than instructing an institution how to bill. The longer treatment lives at reimbursement marketing for medical devices.

The risk posture row is worth a note too. Committees ask about recalls and supply continuity as a routine screen, not as an accusation, and a company that answers plainly with its actual record does better than one that deflects. There is no rule against describing your own field actions, and the constraint is the ordinary one: the description has to be truthful, not misleading, and consistent with the public record. Corrections and removals are separately reported to FDA under 21 CFR Part 806, and recalls are classified and published by FDA under the recall provisions at 21 CFR Part 7, so a hospital can check your version against the agency's in an afternoon. The failure mode is recasting a classified recall as a routine field correction. Answer in the same terms the agency's own record uses, and the row stops being a liability.

The formatting rule that decides the outcome

Give the champion the dossier in the form the committee submits, not in the form that persuaded the surgeon.

That sounds like a production note. It is actually the difference between a submission and a stall. Committee forms ask for cost per case, evidence citations, training hours, and a conversion plan in defined fields. A twelve-page brochure written to excite a clinician gives the champion none of those fields, so the champion either rebuilds the material themselves, which most will not do twice, or files something incomplete, which comes back with questions and loses a full committee cycle.

Two existing pieces go deeper on the committee itself: marketing to value analysis committees covers the process and the professional audience, and hospital value analysis marketing covers submission preparation and the trial period. Use this section as the map and those two as the terrain.

Where Marketing Reaches Each Stakeholder

One message, several delivery paths. The mistake is running a single surgeon-facing campaign and calling it coverage.

Two channel notes specific to orthopedics

Digital targeting is easy and credibility is not. Reaching a named orthopedic surgeon through professional networks, programmatic healthcare inventory, or specialty publishers is a solved problem. Being worth their attention when you arrive is not. Specificity to the subspecialty and the indication is necessary, and it is not sufficient. A hip surgeon and a foot and ankle surgeon share a specialty name and very little else, and a campaign that treats them as one audience reads as a company that does not know the field, which is the fastest way to lose the room before you have said anything. But getting the segmentation right does not by itself earn attention. What earns it is evidence on the exact indication, content pitched at the level of the technique rather than the category, and a credible source, which usually means a peer rather than the company. Worth noting alongside this: not every orthopedic surgeon is a subspecialist, and a substantial amount of community practice is general orthopedics spanning several of these areas, so segmenting purely by fellowship will mis-file a real share of the audience. Digital marketing for spine surgeons is the worked example of doing this at subspecialty resolution.

Assume the surgeon asks an assistant. Increasingly the first description of a new implant that a surgeon encounters is not from your site or your rep. If an AI assistant cannot resolve what your device is authorized for and what evidence stands behind it, the assistant will describe your device using whatever it can find, which is often a competitor's comparison page. That is a marketing problem with a content solution, and it is the reason product pages that state the indication and the evidence plainly now outperform product pages that lead with positioning.

Congress, Labs, and What Sales Needs From Marketing

Orthopedics is one of the few categories where in-person, hands-on marketing still does the heaviest lifting, because the product decision is partly tactile and cannot be made from a screen.

What the field team actually needs, and rarely gets

• The evidence summary, in a version a rep can leave behind and a version a champion can submit
• The objection map: the ten questions surgeons ask about this device, with sourced answers, not talking points
• The conversion plan template, prefilled for the account type
• The instrument and tray specification, in a form sterile processing will accept
• The in service and training plan, with named deliverables and timing
• The reference list, kept current, with permission on file for each reference
• The competitive attribute comparison, cleared through regulatory review before a rep ever sees it

If the field team is building any of those itself, marketing has a gap, and field-created material is also the most common source of unreviewed claims in a device company. Medical device sales enablement covers what marketing owes the field in general terms.

Cadaver and bioskills labs

Hands-on labs are expensive and they persist because a tactile decision cannot be made from a screen, and because for a new technique or an unfamiliar system the training is frequently a prerequisite rather than a persuasion tactic. Institutions can require documented training, and in some cases proctored initial cases, before a surgeon uses a new technology. That puts the lab on the critical path to the first case, not just to the first meeting, and it means the training plan is a gating item in the dossier rather than a courtesy you offer after the win. They are also the point in the plan with the most compliance surface, because they involve travel, meals, faculty compensation, and sometimes honoraria, all directed at physicians.

Payments and other transfers of value made by applicable manufacturers to covered recipients are reportable under the Open Payments program. Both of those terms are narrower and broader than they sound, and both are defined at 42 CFR 403.902. Covered recipients are not only the faculty at the front of the room: the definition reaches physicians, certain other licensed practitioners including physician assistants and nurse practitioners, and teaching hospitals, which matters in orthopedics because so much of this activity happens at academic centers.

There is a second boundary that belongs in the plan rather than in a footnote, and it is the one an orthopedic company is most likely to meet. Programs that direct travel, meals, compensation, or honoraria at the same physicians who select the implant sit next to the federal anti-kickback statute at 42 U.S.C. 1320a-7b, and this category has its own enforcement history. The HHS Office of Inspector General issued a Special Fraud Alert on Physician-Owned Entities on March 26, 2013, addressed specifically to entities that derive revenue from selling implantable devices ordered by their physician-owners for use at hospitals and ambulatory surgery centers, and stated that it views such arrangements as inherently suspect under that statute.

None of that is a marketing determination, and stating it here is not an invitation to make one. The practical planning consequence is that a lab program, an advisory board, and a reference program each carry a compliance workstream with a named owner outside marketing, rather than a compliance checkbox inside it. Build the timeline with that owner in it. Cadaveric lab marketing covers the program mechanics.

Society meetings

For orthopedics the annual meeting is not a lead-generation venue in the way a general trade show is. It is where technique gets demonstrated, where surgeon-to-surgeon conversation happens at scale, and where the peer proof that drives preference is manufactured. The booth's job is to enable a surgeon-to-surgeon conversation, not to capture a badge scan.

Two pieces cover the execution: AAOS conference marketing for orthopedic devices for the show itself, and the HIMSS, AAOS, and RSNA booth planning guide for the planning cycle. Everything shown or handed out at the booth is promotional material and carries the same review obligations as anything else, which the promotional review guide covers.

Peer proof and KOL programs

Surgeon preference is built by other surgeons, so a peer-proof program is core infrastructure rather than a campaign line item: faculty relationships, surgical video, podium presence, publication support, and proctoring. Three constraints apply throughout, and they stack rather than substitute. Content produced with a compensated clinician is an endorsement carrying a material connection disclosure obligation under the FTC Endorsement Guides at 16 CFR Part 255, and the disclosure has to sit on the piece rather than in a contract file. The payment behind that content is separately reportable under Open Payments, and the reported record and the way the relationship is described on the piece should tell the same story. And a compensated clinician's opinion is not substantiation: the evidence behind any performance claim in that content still has to exist independently of the person delivering it. On top of all three, the clinician's own institution frequently has a policy on industry relationships that is stricter than any of them, and journals and societies add their own disclosure rules. The review workflow is in medical device promotional review, and KOL management for medical devices covers program structure.

How Long a Conversion Actually Takes

There is no reliable published average, and this guide is not going to invent one. The duration is controlled by the institution, not by the vendor, and it varies with committee cadence, contract timing, and how many gates the specific hospital runs. A number would be comforting and it would be wrong.

The sequence, though, is consistent, and the sequence is the useful part. Find where your own deals stall and you have something a benchmark could never give you.

Two planning consequences fall out of this table.

Your campaign calendar and the institution's decision calendar are not the same calendar. Marketing runs on quarters. Committees run on their own meeting cadence, and contracts run on renewal dates. A campaign that peaks two weeks after the committee met has missed by a full cycle. For a named-account program, the calendar should be built backward from the committee cadence and contract dates at those accounts, which is the practical reason account-based work pays off in this category specifically.

Measure the gates, not the funnel. A generic marketing funnel does not describe this process and will not tell you where the loss is. A pipeline instrumented against the seven gates above will, and the answer is usually a specific gate rather than general underperformance. Companies most often find the loss at advocacy, which is a content problem, or at contracting, which is a strategy problem. Both are fixable. Neither is visible in a lead count.

Spine, Joint Replacement, Sports Medicine, and Trauma

The chain in this guide holds across orthopedic subspecialties, but the weighting changes, and the changes are large enough to redirect a plan. These four are where the weighting differs most. Hand and upper extremity, foot and ankle, shoulder and elbow, pediatrics, and orthopedic oncology follow the same logic at smaller scale, with the same two approvals.

Spine. The most evidence-scrutinized of the four, and the one where payer coverage and prior authorization sit on top of the hospital process, so the coverage and coding case has to be built earlier and carried further than anywhere else in orthopedics. Spine is also the subspecialty that is not exclusively orthopedic: a large share of spine surgeons trained in neurosurgery rather than orthopedic surgery, so the societies, journals, and meetings split across two training worlds, and a plan built only on orthopedic channels reaches part of the audience and never learns what it missed. A steady migration of decompressions, cervical procedures, and selected single-level fusions into ambulatory surgery centers is changing both the economics and the committee. The two module pieces are marketing to spine surgeons and digital marketing for spine surgeons.

Adult reconstruction, meaning hip and knee replacement. The largest orthopedic implant category, and the one this guide's mechanics describe most exactly: deep system familiarity, heavy instrument trays, a rep in the room, and revision options that decide the choice. Two things distinguish it. A large share of volume has moved to outpatient and ambulatory settings, which changes who owns the economics of the case. And enabling technology now sits between the surgeon and the implant, because a robotic or navigation platform supports certain systems and not others, so the implant sale and a capital sale become one conversation running on two committees, two budget cycles, and frequently an IT and security review. That is a materially different sale and it deserves its own plan rather than an addendum to this one. Note also that episode-based payment arrangements are common in joint replacement, so the economics an institution is judging may be the episode rather than the case.

Sports medicine. A larger share of cases sits in ambulatory surgery centers, which shortens the chain considerably and changes who bears the economics, particularly where physicians hold ownership, which is its own compliance question under the anti-kickback material in section 6 and is not a marketing determination. Expect faster decisions, tighter cost sensitivity, and a review that may be a materials manager and a physician owner rather than a committee. Two wrinkles: capital equipment such as towers, pumps, and shavers tends to travel with the implant relationship, and anything biologic or allograft brings a tissue supply chain and its own institutional review. Marketing to ASC administrators covers that buyer.

Trauma. Inventory and consignment intensive, hospital-driven rather than preference-driven at the margin, and heavily shaped by whatever service line agreement is in force. The distinguishing constraint is availability: trauma cases are unscheduled, so the construct has to be physically in the building, processed, and complete in the middle of the night. That makes the tray footprint, the consignment terms, and the on-call support the actual decision criteria, and it is why the supply chain conversation matters earlier here than anywhere else in orthopedics.

The general treatment that sits above all four is how to market medical devices to surgeons, which covers the eight channels in detail, and the category page is orthopedic device marketing.

Frequently Asked Questions

How do you market a medical device to orthopedic surgeons? You market to the surgeon and to the institution at the same time, because they decide different things. The surgeon decides clinically, on technique, instrumentation, outcomes, and how much the operating room routine has to change, and is reached through clinical evidence, peer proof, society meetings, hands-on training, and the sales rep. The hospital decides commercially, through a value analysis committee that reviews total cost per case, training and inventory burden, and the plan for existing stock, and is reached through a submission dossier the surgeon champion files internally. Neither approval alone converts a case. The most common failure is a strong surgeon relationship with no material the surgeon can take into the committee.

Can an orthopedic surgeon decide which implant the hospital buys? Usually not alone. A surgeon can specify a preference, request an evaluation, and refuse to use a product, and that influence is real. The purchase itself typically runs through a value analysis or new product review process and then through supply chain contracting, and it is constrained by whatever group purchasing or health system agreement the institution already holds. Treat the surgeon as the person who starts the internal process rather than the person who ends it.

What does a hospital value analysis committee want to see for a new implant? Committees vary, but the submission usually has to answer the same set of questions: what the device is authorized to do, what clinical evidence supports the specific claim being made, what the total cost per case is once instruments, disposables, and processing are counted, what the instrument trays require from sterile processing, what training the staff needs, what happens to the inventory of the product being replaced, and who else comparable has adopted it. The practical rule for a device company is to supply that material in the form the committee submits, not in the form that persuaded the surgeon. A sales brochure pasted into a financial review form does not survive the trip.

How long does it take to convert an orthopedic surgeon to a new implant? There is no reliable average, because the clock is controlled by the institution rather than by the vendor. The sequence is consistent even when the duration is not: rep access, a surgeon who agrees to advocate, a submission into a committee that meets on a fixed cadence, committee questions and often a resubmission, a trial or evaluation period, contracting and item master setup, then first case and in service training. Any company that wants a real number should measure its own deals against those gates and find the one where they actually stall, which is more useful than a benchmark.

Does this apply to marketing an orthopedic practice to patients? No. This guide is written for medical device companies that sell orthopedic implants, instruments, and related technology to surgeons and hospitals. Marketing a surgical practice to patients is a different discipline with a different buyer, different regulations, and different channels, and it is not covered here.

---

What to do next

1. Draw your buyer chain for one real account. Name the person in every row of the table in section 1. The rows you cannot fill are your actual gap, and most companies discover they have no name for service line leadership or for sterile processing.
2. Build the dossier before you need it. Every element in section 4, assembled once, in submittable format. Give it to a champion and ask them what they would have to rewrite. Their answer is the specification.
3. Instrument the seven gates. Tag your pipeline against the sequence in section 7 and find the gate where deals die. That single number reorganizes a marketing budget faster than any campaign result.
4. Map the windows at your top accounts. New surgeons, contract renewals, and standardization initiatives are the events that make a displacement possible. A named-account plan that knows which window opens when is a different exercise from a campaign calendar.
5. Need a go-to-market plan that accounts for both approvals? Buzzbox Media works exclusively with medtech companies and healthcare associations, with over 15 years in the category, and builds programs that reach the surgeon and the committee behind them. Book a 30-minute call.

Related reading: marketing to orthopedic surgeons, marketing to value analysis committees, medical device GPO marketing, and the claims workflow behind everything on this page at medical device promotional review. For go-to-market support, see medical device marketing or start at Module 6 of the Medical Device Launch Roadmap.

This guide is general information for medical device companies, not legal, regulatory, or clinical advice. Consult your regulatory affairs, legal, and clinical teams before making any product claim or engaging any healthcare professional.

This guide is published by Buzzbox Media, a healthcare marketing agency in Nashville. We run medical device marketing for medical device companies.

Conferences referenced in this guide

10.0 + Compare

AAOS American Academy of Orthopaedic Surgeons Annual Meeting

March 3-7, 2026 (exhibit hall March 3-5) Orange County Convention Center, Orlando, FL

30,000+ attendees 500+ exhibitors

Cost not published

orthopedics mega

View Details

Continue reading

• HIMSS vs AAOS vs RSNA: How Booth Planning Differs, 12 min read
• Medical Device Promotional Review: What a Promo Piece Needs Before It Ships, 14 min read
• Medical Conference Exhibitor Guide 2026: Costs and ROI, 18 min read